Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 4, 2004, Pages 282-297

  McConnachie, Lisa ^b   Bodor, Miklos ^b   Kowdley, Kris ^b   Levy, Adam ^b   Tung, Bruce ^b   Thummel, Kenneth ^b   Phillips, Brian ^b   Bajpai, Manoj ^b   Chi, Victor ^b   Esmay, Joel D ^b   Shen, Danny D ^b   Ho, Rodney J Y ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIMIMETIC AGENT; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; LIVER ENZYME; MESSENGER RNA; N (3 METHOXY ALPHA PHENYLETHYL) 3 (2' CHLOROPHENYL) 1 (PROPYLAMINE); UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MALE; MOLECULAR PROBE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

BIOPSY; CASE-CONTROL STUDIES; CULTURE TECHNIQUES; CYTOCHROME P-450 CYP2D6; ENZYME ACTIVATION; GENOTYPE; HUMANS; LIVER; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SUBSTRATE SPECIFICITY;

EID: 11144356510     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.12.003     Document Type: Article

References (26)

1. Evans W.E., Relling M.V. Pharmacogenomics translating functional genomics into rational therapeutics. Science. 286:1999;487-491.
2. Zanger U.M., Fischer J., Raimundo S., Stuven T., Evert B.O., Schwab M., et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics. 11:2001;573-585.
3. Human Cytochrome P450 (CYP) Allele Nomenclature Committee Web site. Available from: URL: http://www.imm.ki.se/cypalleles. Accessed October, 2003
4. Rodriguez-Antona C., Donato M.T., Pareja E., Gomez-Lechon M.J., Castell J.V. Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys. 393:2001;308-315.
5. Andersen M.R., Farin F.M., Omiecinski C.J. Quantification of multiple human cytochrome P450 mRNA molecules using competitive reverse transcriptase-PCR. DNA Cell Biol. 17:1998;231-238.
6. Prueksaritanont T., Gorham L.M., Hochman J.H., Tran L.O., Vyas K.P. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab Dispos. 24:1996;634-642.
7. Chauret N., Gauthier A., Martin J., Nicoll-Griffith D.A. In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab Dispos. 25:1997;1130-1136.
8. Chauret N., Gauthier A., Nicoll-Griffith D.A. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos. 26:1998;1-4.
9. Hamelin B.A., Bouayad A., Drolet B., Gravel A., Turgeon J. In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos. 26:1998;536-539.
10. Hickman D., Wang J.P., Wang Y., Unadkat J.D. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos. 26:1998;207-215.
11. Kerry N.L., Somogyi A.A., Bochner F., Mikus G. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan in vitro studies using human liver microsomes. Br J Clin Pharmacol. 38:1994;243-248.
12. Schmider J., Greenblatt D.J., Fogelman S.M., von Moltke L.L., Shader R.I. Metabolism of dextromethorphan in vitro involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharm Drug Dispos. 18:1997;227-240.
13. Coburn J.W., Maung H.M. Calcimimetic agents and the calcium-sensing receptor. Curr Opin Nephrol Hypertens. 9:2000;123-132.
14. Goodman W.G., Frazao J.M., Goodkin D.A., Turner S.A., Liu W., Coburn J.W. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int. 58:2000;436-445.
15. Lowry O., Rosebrough N., Farr A., Randall R. Protein measurement with the Folin phenol reagent. J Biol Chem. 193:1951;265-275.
16. Scarlett L.A., Madani S., Shen D.D., Ho R.J. Development and characterization of a rapid and comprehensive genotyping assay to detect the most common variants in cytochrome P450 2D6. Pharm Res. 17:2000;242-246.
17. Yang Z., Woodahl E.L., Wang X.Y., Bui T., Shen D.D., Ho R.J. Semi-quantitative RT-PCR method to estimate full-length mRNA levels of the multidrug resistance gene. Biotechniques. 33:2002;196. 198, 200 passim.
18. Wang X.Y., Levy R.H., Ho R.J. Development of a semi-quantitative assay to detect full-length CYP2C19 RNA. Biotechniques. 29:2000;364-370. 372-3.
19. Batts K.P., Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 19:1995;1409-1417.
20. Sachse C., Brockmoller J., Hildebrand M., Muller K., Roots I. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics. 8:1998;181-185.
21. Griese E.U., Zanger U.M., Brudermanns U., Gaedigk A., Mikus G., Morike K., et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics. 8:1998;15-26.
22. Lasker J.M., Wester M.R., Aramsombatdee E., Raucy J.L. Characterization of CYP2C19 and CYP2C9 from human liver respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys. 353:1998;16-28.
23. Madani S., Paine M.F., Lewis L., Thummel K.E., Shen D.D. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm Res. 16:1999;1199-1205.
24. Becquemont L., Chazouilleres O., Serfaty L., Poirier J.M., Broly F., Jaillon P., et al. Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. Clin Pharmacol Ther. 71:2002;488-495.
25. Blouin R.A., Farrell G.C., Ioannides C., Renton K., Watlington C.O. Impact of diseases on detoxication. J Biochem Mol Toxicol. 13:1999;215-218.
26. Adedoyin A., Arns P.A., Richards W.O., Wilkinson G.R., Branch R.A. Selective effect of liver disease on the activities of specific metabolizing enzymes investigation of cytochromes P450 2C19 and 2D6. Clin Pharmacol Ther. 64:1998;8-17.